Cytomos Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 27


  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $5.15M

  • Investors
  • 5

Cytomos General Information


Developer of a dielectric spectroscopy technology designed to assist with label-free cell analysis for biomedical research. The company's patented cell analysis technology ensures that every cell is analyzed providing granular information on individual cells and the whole sample population, facilitates automated and quantitative sample assessment, phenotypic drug discovery, and stem cell therapy, enabling medical researchers to find functional endpoints that generate content fingerprints to prepare the right dose thereby making cell-based diagnostics efficient.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Laboratory Services (Healthcare)
Corporate Office
  • 13 Melville Street
  • Edinburgh EH3 7PE
  • Scotland, United Kingdom
+44 0131 000 0000

Cytomos Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytomos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 08-Aug-2023 $5.15M 000.00 Completed Generating Revenue
7. Grant 01-Dec-2022 00000 00.000 Completed Generating Revenue
6. Seed Round 28-Jun-2022 00.000 00.000 00.000 Completed Generating Revenue
5. Seed Round 24-May-2021 00.000 00.00 00.000 Completed Startup
4. Seed Round 26-Jun-2020 00000 00.00 Completed Startup
3. Later Stage VC 23-Apr-2018 00.000 00.000 00.000 Completed Startup
2. Seed Round 01-Mar-2016 $768K $925K 00.000 Completed Startup
1. Seed Round 15-Dec-2014 $157K $157K 00000 Completed Startup
To view Cytomos’s complete valuation and funding history, request access »

Cytomos Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 00,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 126,050 $0.000012 $6.26 $6.26 1x $6.26 15.24%
To view Cytomos’s complete cap table history, request access »

Cytomos Patents

Cytomos Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202318310-D0 Cell selection Pending 30-Nov-2023
GB-202307017-D0 Biological measurement apparatus Pending 11-May-2023
GB-202306372-D0 Biological measurement apparatus Pending 28-Apr-2023 000000000000
GB-201312035-D0 Biological sensing apparatus Inactive 04-Jul-2013 00000000000
US-10933418-B2 Biological analysis apparatus Active 04-Jul-2013 G01N15/0266 00
To view Cytomos’s complete patent history, request access »

Cytomos Executive Team (8)

Name Title Board Seat Contact Info
David Rigterink Chief Executive Officer
Gordon Sharp Chief Technology Officer
Lindsay Fraser Chief Scientific Officer
Fernanda Masri Chief Commercial and Innovation Officer
Alan Raymond Ph.D Chairman
You’re viewing 5 of 8 executive team members. Get the full list »

Cytomos Board Members (6)

Name Representing Role Since
Alan Raymond Ph.D Cytomos Chairman 000 0000
Alister Minty Cytomos Chairman 000 0000
Gino Miele Ph.D Self Board Member 000 0000
Nicola Broughton Ph.D Self Board Member 000 0000
Stewart White Ph.D Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Cytomos Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cytomos Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
British Business Bank Lender/Debt Provider Minority 000 0000 000000 0
Innovate UK Accelerator/Incubator 000 0000 000000 0
Old College Capital Corporate Venture Capital Minority 000 0000 000000 0
Scottish Enterprise Government Minority 000 0000 000000 0
Archangel Investors Venture Capital Minority 000 0000 000000 0
To view Cytomos’s complete investors history, request access »

Cytomos FAQs

  • When was Cytomos founded?

    Cytomos was founded in 2011.

  • Who is the founder of Cytomos?

    Keith Muir Ph.D is the founder of Cytomos.

  • Who is the CEO of Cytomos?

    David Rigterink is the CEO of Cytomos.

  • Where is Cytomos headquartered?

    Cytomos is headquartered in Edinburgh, United Kingdom.

  • What is the size of Cytomos?

    Cytomos has 27 total employees.

  • What industry is Cytomos in?

    Cytomos’s primary industry is Biotechnology.

  • Is Cytomos a private or public company?

    Cytomos is a Private company.

  • What is Cytomos’s current revenue?

    The current revenue for Cytomos is 00000.

  • How much funding has Cytomos raised over time?

    Cytomos has raised $12.7M.

  • Who are Cytomos’s investors?

    British Business Bank, Innovate UK, Old College Capital, Scottish Enterprise, and Archangel Investors have invested in Cytomos.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »